Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, A 5-lipoxygenase inhibitor

Drug Metabolism and Disposition

Volumn 31, Issue 11, 2003, Pages 1352-1360

  Lu, Ping ^a   Schrag, Michael L ^a   Slaughter, Donald E ^a   Raab, Conrad E ^a   Shou, Magang ^a   Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARACHIDONATE 5 LIPOXYGENASE; BUFURALOL; CATALASE; CHLORZOXAZONE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DICLOFENAC; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUVOXAMINE; GLUTATHIONE; HYDROXYUREA; L 594615; L 754394; LIPOXYGENASE INHIBITOR; MEPHENYTOIN; PACLITAXEL; PHENACETIN; PHENAZONE; PHENYTOIN; PROPRANOLOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE; TERFENADINE; TESTOSTERONE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZILEUTON;

ARTICLE; CHEMICAL REACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG HYDROXYLATION; DRUG SCREENING; ENANTIOMER; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; ENZYMOLOGY; HUMAN; HUMAN TISSUE; IC 50; INCUBATION TIME; LIVER MICROSOME; METABOLISM; PRIORITY JOURNAL; RACEMIC MIXTURE;

ARACHIDONATE 5-LIPOXYGENASE; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYDROXYUREA; MICROSOMES, LIVER;

EID: 0142243111     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.11.1352     Document Type: Article

References (50)

1. Awni W, Braeckman RA, Granneman GR, Witt G, and Dube LM (1995a) Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet 29 (Suppl 2):22-33.
2. Awni WM, Braekman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, and Dube LM (1995b) The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclooxygenase inhibitor naproxen in human volunteers. Clin Pharmacokinet 29 (Suppl 2):112-124.
3. Awni WM, Cavanaugh JH, Leese P, Kaiser J, Cao G, Locke CS, and Dube LM (1997) The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 52:49-54.
4. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, and Cavanaugh JH (1995c) Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet 29 (Suppl 2):67-76.
5. Bell RL, Young PR, Albert D, Lanni C, Summers JB, Brooks DW, Rubin P, and Cater GW (1992) The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 14:505-510.
6. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, and Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214.
7. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, and Brooks DW (1991) 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256:929-937.
8. Clarke SE, Ayrton AD, and Chenery RJ (1994) Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24:517-526.
9. Correia MA (1991) Cytochrome P450 turnover. Methods Enzymol 206:315-325.
10. Dube LM, Swanson LJ, and Awni W (1999) Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety. Clin Rev Allergy Immunol 17:213-221.
11. Engel G, Hofmann U, Heidemann H, Cosme J, and Eichelbaum M (1996) Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine formation. Clin Pharmacol Ther 59:613-623.
12. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, and Awni WM (1995) Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 29:77-83.
13. Ha HR, Chen J, Freiburghaus AU, and Follath F (i995) Metabolism of theophylline by cDNA-expressed human cytochromes P450. Br J Clin Pharmacol 39:321-326.
14. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
15. Isreal E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, and Drazen JM (1990) The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 323:1740-1744.
16. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
17. Johnson JA, Herring VL, Wolfe MS, and Relling MV (2000) CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 294: 1099-1105.
18. Jones DR and Hall SD (2002) Mechanism-based inhibition of human cytochromes P450: in vitro kinetics and in vitro-in vivo correlations, in Drug-Drug Interactions (Rodrigues AD ed) pp 387-413, Marcel Dekker, New York.
19. Kaminsky LS and Zhang ZY (1996) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
20. Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, and Kuroiwa Y (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalyzed by human CYP1A2. Br J Clin Pharmacol 45:361-368.
21. Kunze K and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
22. Lo CM, We XX, and Vestal RE (1991) Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. Clin Pharmacol Ther 49:571-580.
23. Lopez-Garcia MP, Danselle PM, and Mansuy D (1994) Thiophene derivatives as new mechanism-based inhibitors of cytochromes P450: inactivation of yeast-expressed human liver cytochrome P450 2C9 by tienilic acid. Biochemistry 33:166-175.
24. Machinist JM, Kukulka MJ, and Bopp BA (1995a) In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokinet 29 (Suppl 2):34-41.
25. Machinist JM, Mayer MD, Roberts EM, Surber BW, and Rodrigues AD (1998) Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos 26:970-976.
26. Machinist JM, Mayer MD, Shet MS, Ferrero JL, and Rodrigues AD (1995b) Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos 23:1163-1174.
27. Madan A, Usuki E, Burton LA, Ogilvie BW, and Parkinson A (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. in Drug-Drug Interactions (Rodrigues AD ed) pp 217-294, Marcel Dekker, New York.
28. Mansuy D, Valadon P, Erdelmeier I, Lopez-Garcia P, Amar C, Girault JP, and Dansette PM (1991) Thiophene S-oxides as new reactive metabolites: formation by cytochrome P450 dependent oxidation and reaction with nucleophiles. J. Am Chem Soc 113:7825-2826.
29. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, and Narimatsu S (1994) Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. Drug Metab Dispos 22:909-915.
30. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
31. Rasmussen BB, Jeppesen U, Gaist D, and Brosen K (1997) Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 19:56-62.
32. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, and Brosen K (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151-159.
33. 14C]naproxen O-demethylase activity in human liver microsomes. Drug Metab Dispos 24: 126-136.
34. Samara E, Cavanaugh JH, Mukherjee D, and Granneman GR (1995) Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Clin Pharmacokinet 29 (Suppl 2):84-91.
35. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, and Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710.
36. Sharer JE and Wrighton SA (1996) Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 24:487-494.
37. Spinler SA, Gammaitoni A, Chariand SL, and Hurwitz J (1993) Propafenone-theophylline interaction. Pharmacotherapy 13:68-71.
38. St. Peter JV, Braeckman RA, Granneman GR, Locke CS, Cavanaugh JH, and Awni WM (1995) The effect of zileuton on antipyrine and indocyanine green disposition. Clin Pharmacol Ther 57:299-308.
39. Sweeny DJ and Nellans HN (1995) Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes. Drug Metab Dispos 23:149-153.
40. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, and Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9-18.
41. 14C]zileuton. a 5-lipoxygenase inhibitor. J Chromatogr 623:390-394.
42. Tjia JF, Colbert J, and Back DJ (1996) Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 276:912-917.
43. Troger U and Meyer FP (1995) Influence of endogenous and exogenous effectors on the pharmaeokinetics of theophylline. Clin Pharmacokinet 28:287-314.
44. Walle T, Walle UK, and Olanoff LS (1985) Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos 13:204-209.
45. Wenzel SE and Kamada AK (1996) Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother 30:858-864.
46. Wong SL, Awni WM, Cavanaugh JH, El-Shourbagy T, Locke CS, and Dube LM (1995) The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers and its metabolites, in normal healthy volunteers. Clin Pharmacokinet 29 (Suppl 2):9-21.
47. Wong SL, Cavanaugh JH, Qian J, Hansen R, and Awni WM (1998) Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline. Am J Ther 5:303-306.
48. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, and Levy RH (2001) Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 70:415-424.
49. Yoshimoto K, Echizen H, Chiba K, Tani M, and Ishizaki T (1995) Identification of the human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 39:421-431.
50. Zhang ZY and Kaminsky LS (1995) Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 50:205-211.